Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation

Authors:

Abstract
Hepatocellular carcinoma (HCC) is an aggressive malignancy. In HCC, mitogen-activated protein kinase (MAPK) signaling is overactivated. The MAPK kinase (MEK) inhibitor trametinib has been approved to treat several types of advanced cancers with a BRAF mutation. Herein, we examined whether trametinib has efficacy against HCC.
Funding Information
  • National Natural Science Foundation of China (81301141, 81100274 and 81570522)
  • Natural Science Foundation of Jiangsu Province (BK20131387)
  • the Priority Academic Program Development of Jiangsu Higher Education Institutions

This publication has 39 references indexed in Scilit: